Company profile

Beijing Mabworks Biotech Co., Ltd.

Privately held: no public share price (Founded 2003, Beijing-based bispecific antibody/NK-cell-engager biotech (licensed obinutuzumab biosimilar MIL62 to Everest Medicines). Multiple company-profile aggregators (CBInsights-style, PrivCo, Tracxn) list it as private; a "810235" HK quote code found via search does not match standard 4-digit HKEX main-board tickers and could not be independently confirmed as a real listing, so treated conservatively as private/unlisted. Sources: https://clinicaltrials.gov/study/NCT06232096 Entity resolved by asset-pipeline-v2.)